Loading...
Market
Primary application of GPT-4b-Micro in longevity research by end of 2025?
2
Resolution / Starting Odds
Cellular reprogramming • 25%
Genetic modification • 25%
Drug discovery • 25%
Other • 25%
Research publications or official statements from OpenAI or Retro Biosciences
Story
OpenAI Develops GPT-4b-Micro AI Model with Retro Biosciences to Enhance Longevity Research, Achieving 50 Times Greater Effectiveness
Jan 17, 2025, 04:00 PM
OpenAI has developed a new AI model, named GPT-4b-micro, in collaboration with Retro Biosciences, a longevity startup funded by Sam Altman. This model is designed to enhance the reprogramming of cells by providing suggestions on how to re-engineer Yamanaka factors, which are crucial for cellular reprogramming. The collaboration aims to extend human life, with the model reportedly allowing researchers to modify two of the Yamanaka factors to achieve over 50 times greater effectiveness. The initiative reflects OpenAI's broader commitment to advancing longevity science through innovative bioengineering solutions.
View original story
Similar markets
Agriculture • 25%
Other • 25%
Energy • 25%
Healthcare • 25%
Stem cell therapy • 25%
Cancer research • 25%
Longevity research • 25%
Neurodegenerative diseases • 25%
6-8 discoveries • 25%
More than 8 discoveries • 25%
0-2 discoveries • 25%
3-5 discoveries • 25%
Cancer Therapy • 25%
Regenerative Medicine • 25%
Other • 25%
Anti-Aging Treatments • 25%
No • 50%
Yes • 50%
Pathogen Detection • 25%
Other • 25%
Antimicrobial Resistance Tracking • 25%
Pandemic Monitoring • 25%
Drug Discovery • 25%
Other • 25%
Healthcare Delivery Improvement • 25%
Clinical Trials Optimization • 25%